Open AccessARA-C, IDARUBICINE AND GENTUZUMAB OZOGAMICIN (AIM) AS SALVAGE TREATMENT IN ADVANCED ACUTE MYELOID LEUKEMIA PATIENTS
Author(s) -
Saveria Capria,
Silvia Maria Trisolini,
Clara Minotti,
Caterina Stefanizzi,
Luisa Cardarelli,
Martina Canichella,
Claudio Cartoni,
Daniela Diverio,
Maria Stefania De Propris,
Marco Mancini,
Alessandra Micozzi,
Robin Foà,
Giovanna Meloni
Publication year - 2012
Publication title -
mediterranean journal of hematology and infectious diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.682
H-Index - 31
ISSN - 2035-3006
DOI - 10.4084/mjhid.2012.072
Subject(s) - medicine , gemtuzumab ozogamicin , myeloid leukemia , refractory (planetary science) , salvage therapy , filgrastim , clofarabine , oncology , chemotherapy , surgery , cytarabine , stem cell , granulocyte colony stimulating factor , cd33 , cd34 , genetics , physics , astrobiology , biology
Long-term survival of relapsed/refractory acute myeloid leukemia (AML) remains a major problem, particularly in patients not eligible for transplantation. We hereby evaluated the feasibility and efficacy of adding Gemtuzumab Ozogamicin to salvage chemotherapy (Ara-C, Idarubicine, Peg-Filgrastim) in relapsed/refractory AML. The main endpoints were: the rate of complete remissions (CR) and the proportion of patients capable of undergoing a stem cell transplant. Fourty-two patients were enrolled. The overall CR rate was 76% and no induction deaths were reported. In 56% of patients, a transplant procedure could be performed. The treatment schedule proved feasible and well tolerated, providing a high CR rate and a useful bridge to transplant.